Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women
Wyeth Pharmaceuticals, a division of Wyeth, announced that the European Commission has granted marketing authorization for CONBRIZA(TM) (bazedoxifene), a selective estrogen receptor modulator (SERM), for the treatment of Postmenopausal Osteoporosis in women at increased risk of fracture.
The World Health Organization's (WHO) fracture risk treatment guidelines and assessment tool for calculating a woman's risk of experiencing an osteoporotic fracture were used in analyses of clinical data that supported the approval of CONBRIZA. Wyeth was one of the first companies to apply the WHO guidelines and tool, first introduced inFebruary 2008.
"Analyses of clinical trial data showed that treatment with CONBRIZA significantly decreased the risk of all clinical fractures and non-vertebral fractures for women who were at a greater risk of osteoporotic fracture," says Gary L. Stiles, M.D., Executive Vice President, Chief Medical Officer,Wyeth Pharmaceuticals. "Importantly, the analyses also showed that the higher a woman's risk of a fracture, the greater the protection she received with CONBRIZA therapy."
Wyeth intends to introduce CONBRIZA in certain European markets following receipt of necessary reimbursement authorizations in those markets. Wyeth is also pursuing regulatory approval of bazedoxifene for the prevention and treatment of postmenopausal osteoporosis inthe United Statesand other countries worldwide.
Other news from the department research and development
